Logo image of GNCA

GENOCEA BIOSCIENCES INC (GNCA) Stock Fundamental Analysis

NASDAQ:GNCA - US3724274010 - Common Stock

0.051
-0.01 (-15%)
Last: 6/2/2022, 8:17:15 PM
0.055
+0 (+7.84%)
After Hours: 6/2/2022, 8:17:15 PM
Fundamental Rating

1

Taking everything into account, GNCA scores 1 out of 10 in our fundamental rating. GNCA was compared to 547 industry peers in the Biotechnology industry. GNCA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, GNCA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GNCA had negative earnings in the past year.
GNCA Yearly Net Income VS EBIT VS OCF VS FCFGNCA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M -50M

1.2 Ratios

Industry RankSector Rank
ROA -95.88%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GNCA Yearly ROA, ROE, ROICGNCA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -1K -2K

1.3 Margins

GNCA does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -1947.12%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNCA Yearly Profit, Operating, Gross MarginsGNCA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -5K -10K -15K -20K

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, GNCA has more shares outstanding
Compared to 1 year ago, GNCA has about the same debt to assets ratio.
GNCA Yearly Shares OutstandingGNCA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M
GNCA Yearly Total Debt VS Total AssetsGNCA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

GNCA has an Altman-Z score of -19.70. This is a bad value and indicates that GNCA is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.24 indicates that GNCA is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z -19.7
ROIC/WACCN/A
WACCN/A
GNCA Yearly LT Debt VS Equity VS FCFGNCA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 1.35 indicates that GNCA should not have too much problems paying its short term obligations.
A Quick Ratio of 1.35 indicates that GNCA should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.35
GNCA Yearly Current Assets VS Current LiabilitesGNCA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

GNCA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.23%, which is quite impressive.
Looking at the last year, GNCA shows a very strong growth in Revenue. The Revenue has grown by 40.44%.
GNCA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 46.87% yearly.
EPS 1Y (TTM)40.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.41%
Revenue 1Y (TTM)40.44%
Revenue growth 3YN/A
Revenue growth 5Y46.87%
Sales Q2Q%264.67%

3.2 Future

GNCA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.21% yearly.
GNCA is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-58.43%
EPS Next 2Y-34.21%
EPS Next 3Y-6.08%
EPS Next 5Y-7.21%
Revenue Next Year-46.87%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GNCA Yearly Revenue VS EstimatesGNCA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2020 2021 2022 500K 1M 1.5M
GNCA Yearly EPS VS EstimatesGNCA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GNCA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNCA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNCA Price Earnings VS Forward Price EarningsGNCA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.18
GNCA Per share dataGNCA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A cheap valuation may be justified as GNCA's earnings are expected to decrease with -6.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.21%
EPS Next 3Y-6.08%

More info and screens

0

5. Dividend

5.1 Amount

GNCA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENOCEA BIOSCIENCES INC

NASDAQ:GNCA (6/2/2022, 8:17:15 PM)

After market: 0.055 +0 (+7.84%)

0.051

-0.01 (-15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2022-05-05/amc
Earnings (Next)07-27 2022-07-27
Inst Owners0.02%
Inst Owner Change0%
Ins Owners4.27%
Ins Owner Change0%
Market Cap3.00M
Analysts77.78
Price Target3.14 (6056.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.57
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB N/A
EV/EBITDA 0.18
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.85
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.03
BVpS0.21
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -95.88%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -1947.12%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.35
Quick Ratio 1.35
Altman-Z -19.7
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.41%
EPS Next Y-58.43%
EPS Next 2Y-34.21%
EPS Next 3Y-6.08%
EPS Next 5Y-7.21%
Revenue 1Y (TTM)40.44%
Revenue growth 3YN/A
Revenue growth 5Y46.87%
Sales Q2Q%264.67%
Revenue Next Year-46.87%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A